The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | The role of checkpoint inhibitors in KRAS-mutated NSCLC
Natalie Vokes, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the efficacy of immune checkpoint inhibitors in KRAS-mutated non-small cell lung cancer (NSCLC). KRAS-mutated lung cancer has shown to be very responsive to immunotherapy, but outcomes may differ based on the mutation subtype. KRAS G12D, which are more common in never smokers than G12C, are more responsive to checkpoint inhibitors. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
